100% of non-muscle invasive bladder cancer patients who generated an immune response to low dose HS-410 and also received standard of care BCG remain disease-free after 2 years DURHAM, NC / ACCESSW...
Original Article: Heat Biologics, Inc.: Heat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation Platform
NEXT ARTICLE